Physicians' Academy for Cardiovascular Education

SGLT2i

Symposium on the role of SGLT2i in tackling cardiorenal risk in diabetes

15' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME

SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events

3' education - Aug. 29, 2021 - Prof. Stefan Anker, MD, PhD

Ground-breaking HF trial with evidence for SGLT2i at EF>40%

3' education - Aug. 29, 2021 - Prof. Frank Ruschitzka, MD

Kidney and HF outcomes with SGLT2i across EF spectrum in HF

3' education - Aug. 28, 2021 - Prof. Rudolf de Boer, MD, PhD

Exciting findings of a pooled analysis of two large HF trials with SGLT2i

3' education - Aug. 27, 2021 - Milton Packer, MD

Another chapter in the SGLT2i book

3' education - Aug. 27, 2021 - Prof. Rudolf de Boer, MD, PhD

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

Practical challenges with SGLT2i therapy in patients with T2DM and CKD

10' education - June 29, 2021 - Alice Cheng, MD - Online CME

Clinical inertia in CKD - What is the rationale for SGLT2i?

10' education - June 21, 2021 - Janaka Karalliedde, MD, PhD - Online CME

Kidney benefit by SGLT2i may be mediated by hematocrit

5' education - June 14, 2021 - Prof. Christoph Wanner, MD

Concomitant use of diuretics and SGLT2i in HF

10' education - Mar. 23, 2021 - Prof. Patrick Rossignol, MD

Reverse cardiac remodeling by SGLT2i in non-diabetic patients with HFrEF

10' education - Feb. 22, 2021 - Carlos Santos-Gallego, MD

SGLT2 inhibitor is kidney protective, even if eGFR <30

3' education - Jan. 26, 2021 - Prof. George Bakris, MD

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD

The six pillars of therapy in HFrEF

3' education - Nov. 15, 2020 - Prof. Marc Pfeffer, MD, PhD

Incredible consistency between two SGLT2i trials in HFrEF

3' education - Sep. 7, 2020 - Milton Packer, MD

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD

Nephroprotective effects with SGLT2i in CKD patients

3' education - Aug. 30, 2020 - Prof. Hiddo Heerspink, PhD

Remarkably similar findings with another SGLT2i in HFrEF

3' education - Aug. 29, 2020 - Prof. John McMurray

Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?

10' education - July 14, 2020 - Prof. Christoph Wanner, MD

The cardiorenal connection and diabetes: Exploring intervention by SGLT2i

10' education - June 23, 2020 - Maria Rosa Costanzo, MD

No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i

5' education - June 11, 2020 - Bettina Kraus, MD

Kidney protection and SGLT2i: What do we know?

10' education - June 9, 2020 - Prof. Mark Cooper, MD

The burden of residual CV risk in the statin era

5' education - Jan. 6, 2020 - Erin Bohula, MD

Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, MD, Glasgow - AHA 2019, Philadelphia

GLP-1RA: where do they fit in CV risk management?

10' education - Oct. 21, 2019 - Prof. John Deanfield, MD

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD

A revolution in treatment of HFrEF with a SGLT2 inhibitor

5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

FDA New Drug Application and Priority Review for SGLT2i for HF across the full spectrum of ejection fraction

News - Nov. 23, 2021

The FDA has accepted a supplemental New Drug Application and granted Priority Review for empagliflozin for the treatment of adults with HF independent of LVEF.

SGLT2i reduces composite of CV death or HF hospitalization in HF patients with LVEF ≥50%

News - Nov. 17, 2021

AHA 2021 This analysis of the EMPEROR-Preserved trail showed that empagliflozin reduced the primary endpoint of time to first event of CV death or HF hospitalization by 17%, compared to placebo, in HF patients with LVEF ≥50%.

SGLT2i improves symptoms in HF

News - Nov. 15, 2021

AHA 2021 The CHIEF-HF study showed that canagliflozin improved symptoms in HF as measured by KCCQ-TSS. The benefits with canagliflozin were observed as early as 2 weeks and sustained until the end of treatment at 3 months.

E-learning Teaming up to tackle cardiorenal risk in diabetes

Accredited e-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

Managing patients with diabetes requires a team approach of physicians in primary care, nephrologists, cardiologists and diabetologists. In this e-learning course, the discussants present a case of a patient with diabetes and comorbidities that shows the complexity of management of such a patient.

Albuminuria reduced by SGLT2i in CKD patients with and without T2DM

Literature - Nov. 8, 2021 - Jongs N, et al. - Lancet Diabetes Endocrinol 2021

The SGLT2 inhibitor dapagliflozin reduced albuminuria compared to placebo in CKD patients with and without T2DM in the DAPA-CKD trial, with a more pronounced effect in patients with T2DM.

SGLT2 inhibitor slows eGFR decline in patients with CKD

Literature - Nov. 8, 2021 - Heerspink HJL et al. - Lancet Diabetes Endocrinol 2021

A prespecified analysis of the DAPA-CKD trial demonstrated that treatment with dapagliflozin attenuated the decline in eGFR compared with placebo, with a greater effect in those with T2DM, higher HbA1c and higher UACR.

SGLT2 inhibitor improves vascular function parameters in patients with HF

Literature - Nov. 1, 2021 - Kolwelter J et al. - ESC Heart Fail. 2021

This phase II randomized study showed that empagliflozin improved vascular function parameters in patients with HF under office conditions and in 24h ambulatory measurements compared to baseline as well as compared to placebo.

Symposium on the role of SGLT2i in tackling cardiorenal risk in diabetes

15' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME
Watch the entire symposium on teaming up to tackle cardiorenal risk in diabetes - The role of SGLT2i: How to overcome clinical inertia?

Watch the entire symposium on teaming up to tackle cardiorenal risk in diabetes - The role of SGLT2i: How to overcome clinical inertia?

No interaction between SBP and effects of SGLT2i on outcomes in HFrEF

Literature - Oct. 27, 2021 - Böhm M, et al. - J Am Coll Cardiol 2021

The SGLT2 inhibitor empagliflozin reduced the risk of the primary endpoint, HF hospitalization and renal outcomes independently of baseline SBP, in patients with HFrEF in the EMPEROR-Reduced trial.

SGLT2i reduces cardiorenal outcomes in HFrEF irrespective of baseline NT-proBNP

Literature - Oct. 18, 2021 - Januzzi JL, et al. - J Am Coll Cardiol 2021

Reduction of CV and renal outcomes by empagliflozin in HFrEF patients in the EMPEROR-Reduced trial was independent of baseline NT-proBNP levels. Empagliflozin reduced NT-proBNP levels, which was associated with a reduction in adverse outcomes.

SGLT2i reduces risk of kidney and CV outcomes across subgroups of baseline UACR

News - Oct. 4, 2021

EASD 2021 This secondary analysis of the DAPA-CKD trial showed that the efficacy and safety of dapagliflozin on kidney and CV outcomes was consistent across subgroups of baseline albuminuria in patients with CKD, with and without T2DM.

Wide distribution of 10-year and lifetime CV risk in patients with diabetes

News - Oct. 1, 2021

EASD 2021 There is a wide distribution of 10-year and lifetime CV risk in diabetes patients with and without a history of CVD. Use of SGLT2 inhibitors and GLP-1RAs was low in all groups.